Study Population
We queried ADR reports for a subset of a broad “men’s health” data consisting of drugs as follows (according to WHODrug): Phospho Diesterase Inhibitors, PDE5i (Sildenafil, Tadalafil, Vardenafil, Avanafil), Prostaglandin Agonist: Alprostadil, Alpha-1 Antagonists (Phentolamine, Tamsulosin, Terazosin, Alfuzosin, Silodosin), Anti Diuretic Hormone analog (Desmopressin), Anti-Cholinergics (Oxybutynin, Tolterodine Darifenacin, Solifenacin, Trospium, Festerodine), Beta-3 Agonist (Mirabegron, Vibegron). We searched for the ADR reports for sildenafil, tadalafil, avanafil, vardenafil, papaverine, and alprostadil in men and extracted the ones in which the corresponding drug was listed as “suspect” or “interacting” before September 29th, 2021. Next, the reports with an uncommon or unknown route of administration for ED treatment purposes were excluded: all routes other than oral and intracavernousal for PDE5is and alprostadil/papaverine, respectively. Of note, we included all men taking these medications regardless of indication.